Recent Updates
Recently added Catalysts

Blink Tears eye in a multidose bottle

Phase 2

Visual Acuity | Small molecule | Ophthalmology |Johnson & Johnson|Last Updated: Apr 27, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05814367Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye DropsPHASE2 COMPLETED 46Apr 6, 2023May 6, 2023Apr 27, 20253 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Monocular logMAR Visual Acuity
10 Minutes Post Eye Drop Administration

Monocular visual acuity was measured at distance (4meter) using a logMAR (Logarithm of Minimal Angle of Resolution) scale under high luminance high contrast lighting conditions. VA was assessed using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual acuity score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Test/ControlEXPERIMENTALEligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (test then control). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated.
Control/TestEXPERIMENTALEligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (control then test). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated.
Interventions
NameTypeDescription
Blink® Tears eye drops in a multidose bottleDRUGControl
Preservative-free investigational lubricating eye drops in a Novelia® eyedropperDRUGTest
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 69 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: * Potential subjects must satisfy all of the following criteria to be enrolled in the study: The subject must: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instruction...

Countries:United States
Unlock Eligibility Criteria